STROBE Statement—Checklist of items that should be included in reports of ***cohort studies***

	Item No	Recommendation	Pages	Lines
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	1	NA
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4	NA
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	8-9	2-7
Objectives	3	State specific objectives, including any prespecified hypotheses	9	5-7
Methods				
Study design	4	Present key elements of study design early in the paper	9-10	10-4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	12	4-5
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	9	15-21
		(*b*) For matched studies, give matching criteria and number of exposed and unexposed	NA	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	10-11	20-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	10-11	5-7
Bias	9	Describe any efforts to address potential sources of bias	11	15-22
Study size	10	Explain how the study size was arrived at	Reported in original publications of both studies	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	11	10-13
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	11	9-22
		(*b*) Describe any methods used to examine subgroups and interactions	11	20
		(*c*) Explain how missing data were addressed	11	24
		(*d*) If applicable, explain how loss to follow-up was addressed	11	14-15
		(*e*) Describe any sensitivity analyses	NA	NA
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Figure 2	

		(b) Give reasons for non-participation at each stage	NA	NA
		(c) Consider use of a flow diagram	Figure 2	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1	
		(b) Indicate number of participants with missing data for each variable of interest	Tables	
		(c) Summarise follow-up time (eg, average and total amount)	13	12-13
Outcome data	15*	Report numbers of outcome events or summary measures over time	13	13-24
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 3, S3-S4	
		(*b*) Report category boundaries when continuous variables were categorized	NA	NA
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	13	17
Discussion				
Key results	18	Summarise key results with reference to study objectives	14-15	16-2
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	17-18	16-4
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15-17	4-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	17	16-20
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	19	13-18

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.